The health landscape sees pivots as companies adjust strategies: Bristol Myers and Pfizer offer discounts on Eliquis, Newcastle University's IVF technique prevents genetic diseases, and Juul's ...

The stock's fall snapped a two-day winning streak.

The US pharmaceutical industry has undergone notable shifts in recent years, influenced by factors such as the COVID-19 ...

In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer discussed what bank industry executives were saying about ...

An international Phase 2 trial will test BMS-986368 as a potentially new oral therapy for managing multiple sclerosis-related ...

This monthly article series screens for high-yielding dividend stocks. Read which stocks made the cut in July 2025.

Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...

Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating ...

Pfizer and Bristol Myers Squibb have launched a direct-to-patient program offering their blood thinner Eliquis at a 40% discount for cash-paying patients.  The list price for Eliquis (apixaban) is ...

An Omnicom spokesperson confirmed that the 2025 MM+M Agency 100 honoree will soon be folded into Omnicom Health subsidiaries.

Topline data were announced from a phase 3 trial evaluating luspatercept-aamt plus Janus kinase 2 inhibitor (JAKi) therapy in adults with myelofibrosis-associated anemia receiving red blood cell (RBC) ...

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent pivotal trial failures—still plans to discuss a potential approval filin | ...